Copyright
©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. May 28, 2006; 12(20): 3253-3258
Published online May 28, 2006. doi: 10.3748/wjg.v12.i20.3253
Published online May 28, 2006. doi: 10.3748/wjg.v12.i20.3253
Evolution in the treatment of metastatic colorectal carcinoma of the liver
Charlotte E Ariyan, Ronald R Salem, Department of Surgery, Section of Surgical Oncology, Yale University School of Medicine, Tompkins 202, 333 Cedar Street, New Haven, CT 06520, United States
Author contributions: All authors contributed equally to the work.
Correspondence to: Ronald R Salem, Department of Surgery, Section of Surgical Oncology, Yale University School of Medicine, Tompkins 202, 333 Cedar Street, New Haven, CT 06520, United States. ronald.salem@yale.edu
Telephone: +1-203-7853577 Fax: +1-203-7374067
Received: March 29, 2006
Revised: April 6, 2006
Accepted: April 16, 2006
Published online: May 28, 2006
Revised: April 6, 2006
Accepted: April 16, 2006
Published online: May 28, 2006
Abstract
Metastatic colorectal cancer to the liver is associated with a uniform poor prognosis without treatment. Advances in therapy over the past decades have now allowed surgical resections of the liver to occur with a low morbidity and mortality. Improvements in chemotherapy regimes have paralleled technical improvements and now allow a new group of patients to become eligible for surgical resection. This chapter will review the recent advances in surgical and chemotherapeutic regimes in metastatic colorectal cancer to the liver.
Keywords: Ethical tensions; Metastatic; Colorectal Carcinoma; Liver